We're excited to share that participants have been randomized in the KaiNETIC global Phase 3 clinical program of ribupatide (KAI-9531), a dual GLP-1/GIP receptor agonist, for treatment of #obesity or overweight: https://t.co/EEwsolgYat
#KaileraTx#JPM2026#GLP1
We remember Dora Menchaca, an Amgen scientist, mentor, mother, and wife who was aboard Flight 77 on September 11.
At our Thousand Oaks headquarters, a bronze sculpture in her honor stands as a place of reflection.
Today, we pause to honor her and all the lives lost.
🔗https://t.co/sX1xgMPBOv
Also had a fantastic conversation with Kailera CEO Ron Renaud (@biotech1969) and @TimOpler about China and the US, and what I think is biotech's most important story
We’re thrilled to welcome Kailera Therapeutics as a Silver level member of the OAC Corporate Council! Thank you for your commitment to supporting our mission to educate, advocate and empower individuals affected by obesity. We couldn't do this work without partners like you!
We’re thrilled to welcome Jamie Coleman as Chief Commercial Officer! Jamie is a commercial leader with nearly 25 years of experience across product lifecycle and therapeutic areas leading transformative brands, including Zepbound® https://t.co/kbndccrM1I #KaileraTx#Obesity